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Beyond disability: measuring the social and personal consequences
of osteoarthritis
BY ALISON J. CARR
King’s College, London University, London, U.K.
Summary
Objective: Measuring the impact of osteoarthritis has traditionally focused on the disease (measures of impairment),
functional disability and latterly, general health status or quality of life. This paper highlights the importance of
measuring the wider personal and social consequences of OA both at a population and an individual patient level.
Design: The World Health Organisation definition of handicap is used to describe this wider impact of disease and
measures of handicap, both generic and disease-specific are reviewed. The measurement of handicap in OA is
illustrated by the use of the Disease Repercussion Profile in a clinical trial of orthopaedic out-patients with OA and low
back pain. These data are compared to routine clinical handicap data collected on consecutive patients with
rheumatoid arthritis attending a di#erent outpatient clinic.
Results: OA patients reported handicap in six areas of their lives: functional and social activities, relationships,
socio-economic status, emotional well-being and body image. The prevalence was similar to that reported by RA
patients. OA patients reported more severe handicap than RA patients in each of the 6 areas (F ratios 4.97–55.67) and
the di#erences were statistically significant (P values 0.03–0.0001) for all dimensions except functional and social
handicap. The LBP patients scored slightly more severe handicap on all dimensions than the OA patients but these
di#erences did not reach statistical significance. However, they scored significantly more severe handicap than the RA
patients (F ratios 8.49–174.72, P<0.0001).
Conclusions: These data suggest that the psychosocial impact of OA may have been underestimated and highlight
the importance of going beyond disability in assessing the impact of OA. Measurement of the wider impact of OA can
be achieved using disease-specific and generic measures of handicap. The choice of tool will depend upon the setting
(research or clinical practice) and the purpose of measurement.
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OSTEOARTHRITIS (OA) is a common, chronic
progressive disease characterized by pain and
increasing disability. It is one of the leading causes
of physical disability in Western Industrialized
countries and is associated with significant health
and welfare costs [1, 2]. At an individual level, the
indirect costs of osteoarthritis are considerable.
It is responsible for losses in work and social
activities and for di$culties performing self-care
tasks [3, 4, 5]. The personal impact of OA may
be exacerbated by the generally negative view of
OA held by society and clinicians whose current
interventions are unlikely to alter long term out-
come. Studies of patients with moderate and severe
OA indicate that, in addition to the functional and
work-related problems, it has a significant impact230on emotional well-being and relationships with
friends, family and spouses, and also a#ects body
image and self-esteem [6].Received 3 December 1997; accepted 16 September 1998.
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The impact of chronic disease can be assessed at
several levels from the specific biological aspects
of disease to the more global personal and social
consequences of disease. A number of models of
disease impact have been proposed to take account
of these levels. One of the most widely quoted is
the World Health Organisation (WHO) model of
impairment, disability and handicap [7]. In this
model, impairment is any loss or abnormality of
psychological or anatomical structure or function.
Disability is any restriction or lack (resulting from
impairment) of ability to perform an activity in the
manner or within the range considered normal for
a human being. Handicap is the disadvantage an
individual experiences resulting from an impair-
ment or disability, that limits or prevents the
fulfilment of a role that is normal (depending on
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vidual. Although the definitions suggest a linear,
hierarchical relationship between impairment,
disability and handicap, clinical experience in
rheumatology refutes this. A subgroup of patients
function normally despite severe seropositive
RA, women report higher functional disability
scores than men with similar disease severity and
duration and around 20% of patients report severe
pain and disability with no evidence of disease
activity [8]. An alternative model for disease
impact based on the WHO definitions has been
proposed [9] (Fig. 1).
Some concern has been expressed about the
negative connotations associated with the term
handicap. This has led some authors to propose
alternative models of disease impact which refer tothe social consequences of disease as disability.
Indeed, the WHO has recently revised its classifi-
cation, replacing the terms disability and handicap
with activities and participation [10]. However,
what is common to all models, regardless of the
terminology adopted, is an attempt to describe the
personal and social consequences of disease which
arise from the complex interaction between the
disease, the individual and his/her environment. In
other words, they attempt to go beyond the con-
cept of disability or activity limitation to describe
and understand the processes whereby some indi-
viduals become socially disadvantaged by their
disease. In this sense, the underlying concept is
more important than the label used to describe it.
This paper will use the WHO concept of handicap
to describe the personal and social consequences
of disease on the basis that clear definitions exist
which are widely used and understood.FIG. 1. Venn diagram showing the relationship between
impairment, disability and handicap. The Venn diagram
illustrates the relationship between impairment, disabil-
ity and handicap as it occurs in the general population.
The majority of people do not experience impairment,
disability or handicap (area A). Some people have
impairments but no disabilities or handicaps (area B),
for example, people who have evidence of osteoarthritis
on X-ray but are asymptomatic. Others are handicapped
without impairments or disabilities, i.e. not health-
related handicap (area C). An example would be people
who are unemployed for reasons unrelated to their
health. A number of people have impairments and handi-
caps without experiencing disabilities (area D), for
example, a teenage girl with a port wine stain on her
face who is socially handicapped. Health-related dis-
abilities only occur when some impairment is present
(area E). A proportion of the population experience
impairment, disability and handicap (area F). (From:
Carr AJ, Thompson PW. Towards a measure of patient-
perceived handicap in rheumatoid arthritis. Br J
Rheumatol 1994;33:378–82). Reproduced by permission of
Oxford University Press.
Permission to reproduce this figure
electronically not grantedDefining handicap
Handicap, the social consequence of disease, is
specific to individuals and depends not only on the
severity of disease, but also on his/her life role.
The latter is itself dependent on many factors
including physical and psychological makeup,
expectations of family and society and individual
aspirations [9]. This means that the same impair-
ment can result in di#erent handicaps and handi-
caps of varying severity. For example, a young
patient may su#er painful hand deformity
(impairment) rendering her unable to write or use
a keyboard (disability), leading to the loss of her
job as a secretary (handicap). However, for an 80
year-old woman the same impairment and dis-
ability may result in social isolation because she is
unable to write to friends or get dressed to go out
to meet them. The degree to which an individual is
handicapped depends on the perceived importance
of the role that can no longer be filled. Thus, the
degree to which the young secretary was handi-
capped by losing her job might be influenced by
whether she was a single parent or living with her
employed husband.
Handicaps can be defined with reference to
either society’s or the individual’s perspective and
discrepancies between the two can be consider-
able. Society, in the guise of employers and
healthcare professionals, among others, defines
individuals as handicapped or disadvantaged
when they are unable to fulfil roles which someone
of a similar age, sex and social background would
be expected to perform. This assessment takes
no account of the individual’s expectations or
232 Carr: Measuring the consequences of osteoarthritisaspirations. For example, a keen amateur
musician with relatively mild rheumatoid arthritis
may find that he is unable to play his instrument,
but is able to continue work as a personnel
manager. From society’s perspective he would not
be considered handicapped, but at a personal level,
the loss of what is, to him, an important activity
would represent considerable disadvantage. Both
views are valid but suited to di#erent situations.
In epidemiological studies, some comparison with
a defined norm is useful and the use of society-
based measures of handicap would be appropriate.
At a clinical level, however, assessment of the indi-
vidual’s perception of the impact of disease and the
particular problems which he/she experiences is
more relevant.Measuring handicapMEASURES OF IMPAIRMENT, DISABILITY AND QUALITY
OF LIFE
Measures of impairment (X-rays, laboratory
tests) and disability are well established in
rheumatology but, alone, do not describe the
complete impact of disease on individuals or
populations. This paper contends that much can be
gained in terms of identifying clinically important
problems, in assessing the e#ectiveness of inter-
ventions and describing the natural history of
disease by going beyond disability. Quality of
life measures have attempted to capture this
wider impact but most existing measures are
summary measures of impairment, disability and,
in some cases, handicap, which provide an overall
assessment of disease impact.
Measurement of impairment in OA is
synonymous with assessment of joint damage
(using X-rays and other imaging techniques),
disease activity (laboratory assessments) and joint
involvement (clinical examination). Measures of
disability in OA have focused on physical function
and include ‘objective’ measures of performance,
clinician ratings (for example, the Harris Hip
Score [11]) and patient self-assessments such as the
WOMAC [12] and Lesquene Indices [13]. Their
primary use has been in research where they have
been used to assess the relative e$cacy of nonster-
oidal anti-inflammatory drugs or to describe the
outcome of joint replacement surgery. The search
for measures which incorporate the broader
aspects of health and consequences of disease has
led to an upsurge of interest in quality of life
measures. Most of these measures are generic
rather than disease-specific and either provide
unitary values of health status (health indices)such as the Quality of Well-Being Scale [14]
and the Euroqol [15], or measure a number of
dimensions of health status (Health Profiles), such
as the SF-36 [16]. Their biggest limitation is that
they are not based on an agreed definition of
quality of life, which means that, in practice, they
measure a combination of impairment (symptoms),
disability and some social problems [17]. Despite
this drawback, they are increasingly widely used
in research and clinical practice.Handicap measuresINTERNATIONAL CLASSIFICATION OF IMPAIRMENTS,
DISABILITIES AND HANDICAPS (ICIDH)
The measurement of handicap in chronic disease
has progressed slowly. This is partly due to the
ascendancy of quality of life measures and partly a
function of the lack of user-friendly, relevant
measures. However, a small number of measures
are available, the earliest of which was the ICIDH
[18]. This system of classification was designed to
capture what may happen in association with a
health condition and complements the Inter-
national Classification of Diseases (ICD). It is a
standardized, structured tool, completed by the
clinician, containing a series of codes for classify-
ing levels of impairment, disability and handicap.
It has been used to assess disabled people in
institutional settings [19], in population surveys
[20, 21] and for administrative purposes [22]. In all
these situations, problems have been reported with
its use which relate to the exact format of the
codes in the classifications and the assignment to
these codes, the purpose for which it is used and
the relationship between impairment, disability
and handicap. The handicap scales in particular
have proved di$cult to use. Experience of the
clinical use of the handicap scales indicates that a
considerable amount of time is required to gather
enough information to allow accurate classi-
fication of handicap [19, 23, 24]. This results in
problems with sta# co-operation [24, 25]. A further
problem, which has implications for the reliability
of the classification, is that di#erent health pro-
fessionals rate handicap di#erently [26]. The gen-
eral consensus was that while the classification
served a purpose, further development work was
needed, particularly with regard to the concept of
handicap, to achieve standardisation and agree-
ment about how it should be used. The WHO has
just completed this development work and pro-
duced a new classification system, ICIDH-2 [10]
which is currently undergoing field tests. In
this new classification system, the concepts of
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activity and participation and the process of dis-
ablement, i.e. the limitation of activity or the
prevention of participation, is mediated by contex-
tual factors which may be environmental or per-
sonal. The ICIDH-2 is proposed as a multipurpose
tool: to measure outcomes in research; as a clinical
tool in needs assessment, vocational assessment
and rehabilitation; to assist with curriculum
design in education; and as a social policy tool for
social security planning, compensation systems
and policy design and implementation. Field tests
of the ICIDH-2 are in progress which should
provide information about its practical utility
and whether the problems of ICIDH-1 have been
e#ectively overcome.THE LONDON HANDICAP SCALE
This self-completed questionnaire was developed
as a generic measure of handicap [27]. It measures
the handicap state of an individual by comparison
with the ‘normal’ activities of someone of a similar
age and sex who does not have health problems.
It is a standardized measure in which the dis-
advantage of the individual in comparison with
society determined norms is measured in each of
the six survival roles identified in the ICIDH
(orientation, physical independence, mobility,
occupation, social integration, economic self-
su$ciency) by asking patients to select from a
series, the situation which most closely resembles
their own. The handicap is quantified using utili-
ties. The reliability and validity of the London
Handicap Scale have been established [27] and its
use in clinical research indicates that it is quick
and easy for patients to complete [28]. This tool
only measures the individual’s perception of him/
herself as handicapped to the extent that his/her
views coincide with those of the general public. It
is therefore of limited value in identifying handi-
cap in clinical practice, but of great benefit in
epidemiological and health services research such
as clinical trials, needs assessment exercises and
descriptive studies of groups.related to functional and social activities in thatDISEASE REPERCUSSION PROFILE (DRP)
The DRP was designed as a disease-specific
measure of handicap for rheumatoid arthritis
[9, 29] but has recently been validated in other
conditions including OA [30]. It is an indi-
vidualized measure which uses a combination
of open questions and graphic rating scales to
produce a profile of perceived handicap in six
domains: functional activities, social activities,socio-economic status, relationships, emotional
well-being and body image. It is a self-completed
questionnaire on which patients are able to specify
the particular handicap they are currently experi-
encing in each of the domains and rate its severity
on a 10-point graphic rating scale. Scoring involves
plotting the handicap rating for each domain on a
bar chart to obtain a handicap profile for each
patient. The purpose of the DRP is routine use in a
clinical setting to facilitate the most appropriate
use of treatment interventions. Its reliability and
validity have been established and it is being used
in routine clinical practice and as an outcome
measure in several studies. Comparative studies
have indicated that it is complementary to the
London Handicap Scale [28].RELATED MEASURES
There are two established measures of quality of
life which come close to measuring patient-
perceived handicap. The Schedule for the
Evaluation of Individual Quality of Life (SEIQoL)
[31], is an individualized measure of quality of life
in which patients are asked by an interviewer to
list the five areas of life that they consider to be
most important to their overall quality of life. They
are then asked to rate their current status in each
of these areas on a visual analogue scale (VAS). To
quantify the relative weight of each of these areas
to the individual’s perception of quality of life,
they are presented with 30 hypothetical people
profiles and are asked to rate on a VAS the quality
of life they associate with each profile. This
tool comes close to measuring the individual
handicap resulting from disease but its usefulness
has been limited because it requires a trained
interviewer to administer it, making it time con-
suming and expensive. However, a self-completed
version has now been validated [32] which may
be suitable for use in clinical practice as well as
research.
The Patient Generated Index (PGI) [33] is very
similar to the SEIQoL in structure, asking patients
to specify five areas of their lives, or five activities
that are important to them and then asking them
to rate how badly each area is a#ected by their
condition. Weighting is achieved by the use of
spending points where patients are given 12 points
to spend to improve all or some of those areas or
their lives. The PGI has been used in cohorts of
patients with chronic disease, including RA,
atopic dermatitis [34] and low back pain.
The MACTAR Patient Preference Questionnaire
[35] goes some way towards measuring handicap
234 Carr: Measuring the consequences of osteoarthritisit assesses the disadvantage experienced by
individuals in fulfilling roles.Summary of handicap measures
Three methods for measuring handicap in OA
have been reviewed. They di#er in their structure,
content and application but all attempt to measure
the wider personal and social consequences of
disease. The ICIDH is a clinician-administered
system of classification that is highly structured
and which classifies individuals according to
population-derived ‘norms’. In this respect it is
similar to the London Handicap Scale, which is
based on the survival roles listed in the ICIDH.
The London Handicap Scale has been specifically
designed to measure the relative handicap levels
in populations or groups of patients and to this
extent is most useful as an outcome measure in
clinical trials or epidemiological studies, or to
identify need in needs-assessment exercises. It may
not be relevant at an individual level in clinical
practice, where the Disease Repercussion Profile
is probably the most appropriate measure. The
DRP is individualized rather that standardized,
allowing patients to express their perceived dis-
advantage rather than reflecting the degree to
which they would be considered disadvantaged by
comparison with societal ‘norms’. To this extent, it
is useful in clinical practice to identify specific
problems that may be amenable to intervention, or
to explain persistent non-response to intervention.
The ICIDH and London Handicap Scales are
generic measures, facilitating comparisons be-
tween di#erent clinical populations, whilst the
DRP is disease-specific. There are advantages to
both approaches which will be discussed later.
What should be apparent is that the handicap
measures reviewed can be seen as complementary
to each other, and that selection of a measure
will depend on the situation and purpose of
measurement.Individualized versus standardized measures
of handicap
One of the contentious issues in health status
measurement is whether instruments should be
highly standardized, requiring the patient to select
a response from a set of pre-determined responses,
or whether they should be flexible enough to allow
patients to specify their own particular problem or
evaluation. Arguments for the use of standardized,
highly structured measures are based on the
premise that such instruments are necessarily
more generalizable than individualized measuresand easier to manipulate statistically. They are
therefore seen to be more useful in clinical
trials or epidemiological studies where groups or
populations of patients are being compared. How-
ever, they are less useful in clinical practice for
identifying the specific problems of individual
patients. Individualized measures, on the other
hand, are likely to be more e#ective in clinical
practice. Some individualized measures such as
the DRP and SEIQoL have been used as outcome
measures in clinical trials and have demonstrated
generalizability and ease of statistical manipu-
lation. A stronger argument for the use of indi-
vidualized measures, particularly in areas of
health which are personal and di$cult to quantify,
is provided by evidence from several comparative
studies of doctors’ and patients’ assessment of
disease and quality of life. These suggest that the
traditional method of clinical decision-making in
which the clinician makes judgements about the
impact of disease on patients is suboptimal in
meeting patients’ needs because of the disparity
between doctors’ and patients’ assessments of dis-
ease activity and impact [36–41] and doctors’
inability to recognize and treat aspects of disease
which are important to patients [43–45]. Moreover,
patients’ perceptions of chronic disease have been
shown to be central to the successful adaptation to
chronic illness [46].Generic versus disease-specific measures
Another debate in health status measurement
centres on the relative value of generic and
disease-specific measures. Generic measures assess
basic health values that are relevant to everyone’s
health status and well-being as opposed to any
particular age, treatment or disease group. They
make it possible to compare outcomes across
diagnostic groups and between di#erent inter-
ventions [47]. They therefore play an important
role in cost–utility studies and economic analyses
[48]. They are sensitive to variations in functional
status and well-being, but because they give no
information about the causes of those variations,
they may be of limited use in a clinical setting
where a guide to selection of treatment or adjust-
ment of drug dosage is required. This is tradition-
ally the domain of disease-specific measures. The
use of disease-specific instruments is of particular
importance when measuring impairment and dis-
ability because biological attributes and func-
tional abilities are a function of the disease. For
example, active synovitis is an important indicator
of disease activity in an inflammatory arthritis but
would be an inappropriate marker in diabetes.
Osteoarthritis and Cartilage Vol. 7 No. 2 235Similarly, assessment of activities of daily living
(ADL) function involving upper limb dexterity is
an important disability measure in RA but not
asthma. Conversely, specific handicap, such as the
socio-economic disadvantage resulting from an
inability to work, may be common to several dis-
eases and could therefore be potentially measured
by both disease-specific and generic instruments.
Comparative studies of generic and disease-
specific measures have demonstrated little di#er-
ence in responsiveness to clinically important
change in RA [48] although there are di#erences
in the ability to detect change or discriminate
between patients on particular parameters. This is
related to the di#erence in structure of the various
measures. For example, in OA patients, the
WOMAC (disease specific) is more sensitive in
detecting knee disabilities than the SF-36 (generic)
which is better at detecting co-morbidity and dif-
ferent levels of general health status [50]. This
is not surprising since the WOMAC is designed an
a measure of functional disability, rather than
general health status, whereas, the SF-36 is a
measure of general health status which includes
an assessment of functional disability but also
assesses emotional functioning and roles, social
functioning and energy. The consensus seems to be
that there is a role for both generic and disease-
specific measures in outcome assessment which
depends on the purpose of measurement.100
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FIG. 2. The percentages of patients with OA and RA
reporting an impact of disease in each of the six areas
of their lives. **P<0.0001. The P values refer to chi-
square statistics for di#erences between patients with
RA and OA in those categories. , function; , social;
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image.The measurement of handicap in OA
Osteoarthritis has traditionally been considered
a benign disease except in its end stages. However,
the use of handicap tools to assess the impact of
OA have indicated that its impact, even in mild
disease, may have been significantly under-
estimated and highlight the importance of going
beyond measures of disability in assessing the
impact of OA. The implications of measuring
handicap in OA will be discussed with reference to
data collected from a number of studies although
the bulk of the data on OA was collected during
a clinical trial in an orthopaedic outpatient
department.
Patients for whom handicap data are presented
were recruited from a number of sources. Patients
with moderate OA were recruited from general
practitioner referrals to orthopaedic outpatient
clinics at two hospitals to participate in a clinical
trial of the management of non-surgical referrals.
They were over 18 years and judged by the Con-
sultant Orthopaedic surgeon as unlikely to require
surgery. Patients with severe OA were recruited
from the waiting lists for total knee replacementsurgery at the same hospitals. Patients with low
back pain were participating in the same clinical
trial as those with moderate OA and fulfilled the
same inclusion criteria. Patients with RA were
consecutive patients attending Rheumatology out-
patient clinics in a di#erent hospital, also in the
south of England. They were not participating in
any clinical trial but were all over 18 years.
As a precursor to the trial, 106 patients with
moderate (N=81) and severe OA (N=25) were sent
a survey questionnaire containing open-ended
questions about the impact of their arthritis on
their lives. This questionnaire was validated in a
previous survey of 438 patients with RA [9] for
whom the comparative data is shown. Random
samples of 18 patients with moderate and 18
patients with severe OA were drawn from the 106
patients who participated in the postal survey.
In-depth, semi-structured interviews were con-
ducted with these patients to explore the impact of
OA. Analysis of the questionnaire data identified
six main themes or areas which were a#ected by
OA. These were the same as those previously
identified by RA patients and included: functional
activities, social activities, socio-economic status,
relationships with families, spouse and friends,
emotional well-being and body image. The percent-
ages of the 106 OA patients reporting that OA had
an impact in each of the six areas are shown in
Fig. 2 which also gives the data from the previous
RA survey for comparison. These six areas of
impact were confirmed by the semi-structured
interviews. The data show that for most patients,
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Mean handicap (DRP) scores in patients with OA, RA and low back pain
Handicap
dimension
RA OA LBP
Functional activities 5.28 (SD 3.76) 7.52 (SD 3.40) 8.03 (SD 2.88)
Social activities 4.76 (SD 3.39) 6.81 (SD 4.02) 7.03 (SD 2.88)
Emotional well-being 3.62 (SD 4.20) 8.74 (SD 2.3) 8.83 (SD 1.42)
Body image 3.40 (SD 3.40) 6.21 (SD 3.61) 8.06 (SD 2.51)
Relationships 2.59 (SD 3.87) 7.61 (SD 3.12) 8.60 (SD 1.56)
Socio-economic 2.10 (SD 3.48) 3.39 (SD 4.41) 6.03 (SD 4.57)OA has an impact on their functional and social
activities and their emotional well-being, with
fewer reporting an impact on relationships, socio-
economic status and body image. Whilst the data
for RA are not directly comparable because the RA
patients were drawn from a di#erent population,
they nevertheless give an indication of the relative
impact of RA and OA on people’s lives. RA has
traditionally been considered a more severe dis-
ease but the comparative data suggest the preva-
lence of impact is similar in the two patient
populations, with more OA patients reporting a
negative impact of disease on their emotional well-
being. The patient groups had similar age distri-
butions, with the OA group slightly older (mean
age 64 years, SD 15) than the RA patients (mean
age 62 years, SD 13, min–max 22–89). These data
give an estimate of the prevalence of the impact of
OA in this population of patients but tell us little
about the severity of impact.
Data on the severity of impact were obtained
from the Disease Repercussion Profile (DRP)
which was administered to all trial patients with
moderate OA and low back pain (LBP) at the
baseline assessment and to 134 consecutive
patients with RA attending a Rheumatology out-
patient clinic (as part of routine clinical practice).
There were approximately equal proportions of
men and women in the OA and the LBP groups but
the male:female ratio in the RA group was 1:3. The
mean age of patients with RA was slightly greater
(61 years, SD 12, min–max 22–84) than those with
OA (52 years, SD 18, min–max 20–84) and LBP (47
years, SD 15, min–max 22–79). All groups were
moderately functionally disabled on disease-
specific measures of functional disability (Health
assessment Questionnaire, WOMAC and Oswestry
Back Pain Disability Questionnaire). Handicap
profiles on the DRP indicate more severe handicap
on all 6 dimensions in the OA compared with the
RA patients (F ratios 4.97–55.67) and the di#er-
ences were statistically significant (P values 0.03–
0.0001) for all dimensions except functional and
social handicap. The LBP patients scored slightlymore severe handicap on all dimensions than the
OA patients but these di#erences did not reach
statistical significance. However, they scored sig-
nificantly more severe handicap than the RA
patients (F ratios 8.49–174.72, P<0.0001). Table I
gives the mean handicap scores from the DRP for
OA, RA and LBP patients. Each dimension is
scored from 0–10 where 10 represents the most
severe handicap. Once again, the comparison
between the OA and LBP patients is more robust
than that with the RA patients because the OA
and LBP patients were drawn from the same popu-
lation of patients referred to orthopaedic surgeons
and were participating in the same clinical trial.
The RA patients were routine outpatients from a
di#erent hospital, living within a di#erent com-
munity. Nevertheless, all the patients are similar
to the extent that they live within the same
region of England and were all attending hospital
outpatient departments.
Taken together, these data demonstrate the
extensive prevalence and severity of the wider
impact of OA and highlight the importance of
going beyond functional disability in assessing the
burden of disease. If measurement does not extend
beyond functional disability a large proportion of
the burden of disease, particularly in terms of its
emotional and psychological costs will not be
identified. It should be pointed out that these data
reflect the patients’ perceptions of themselves as
disadvantaged. If the same patient populations
had been assessed using the London Handicap
Scale the results might have been di#erent
because they would have been assessed within the
framework of what society would consider normal
levels of activity or participation for people with-
out disease. However, whilst knowledge of devia-
tions from ‘normal’ activities are important for
epidemiological studies, at a clinical level, it is
the patient’s perception of their condition which
determines: the use of primary health care
services, over the counter medication and
ancillary services (such as physiotherapy); time
Osteoarthritis and Cartilage Vol. 7 No. 2 237o# work; and the psychological and emotional
sequelae.
At an individual patient level, going beyond
the assessment of disability can have important
clinical benefits. Firstly, it may be possible to
intervene to alleviate some aspects of handicap,
even when the impairment and disability are not
readily treatable. To take an example in OA,
the inability to walk outdoors for someone with
moderate knee OA may not be immediately
amenable to change (until, perhaps, the joint is
replaced), but the resultant handicap (being house-
bound and socially isolated) may be alleviated by
the use of a wheelchair. Secondly, measuring
handicap may provide important clinical informa-
tion which would not be collected by measures of
impairment or functional disability, such as infor-
mation about major life events or changes in
circumstances and factors likely to influence com-
pliance with interventions. Finally, measurement
of patient-perceived handicap can be used as a
basis for the formulation of treatment plans. This
is the case in one Rheumatology clinic where DRP
scores are used to inform the clinical interview
and treatment decisions are based on a combi-
nation of the clinical data and the DRP. The DRP
is also being used as the basis for goal-setting in
the management of patients with inflammatory
arthritis and is being formally evaluated by
means of a randomized, controlled trial to see
whether this approach improves patient and
disease outcomes.Summary
Osteoarthritis has traditionally been considered
a relatively benign disease compared with RA
but the studies described here suggest that the
psychosocial impact of OA may have been under-
estimated. These studies report high levels of
handicap in patients with moderate OA using an
individualized tool which measures how much the
patient perceives him/herself to be handicapped
(DRP) and highlight the importance of going
beyond a consideration of impairment and func-
tional disability in assessing the impact of OA.
Measuring these personal and social consequences
of disease can provide relevant information for
health and social policy planning and implementa-
tion, for epidemiological studies and, at a clinical
level, for disease management in individual
patients. The discussion about what label this
wider impact of disease should be given is ongoing.
In the meantime, validated measures of handicap
(relevant both for population surveys and clinical
practice) exist which can provide assessments ofthe personal and social consequences of OA and
which are increasingly used in clinical practice
and research.References
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